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Abstract
Background: Serum sialic acid levels are positively correlated with coronary artery disease and inflammation.
Although sialic acid is a non-specific marker, it is considered sensitive likely due to its influence in sialylation of
glycoprotein structures all over the body.
Objectives: We hypothesized that dietary supplementation with N-acetylneuraminic acid (Neu5Ac), a type of sialic
acid, will have profound effects on high fat diet- (HFD-) induced inflammation and oxidative stress in view of the
widespread incorporation of sialic acid into glycoprotein structures in the body.
Methods: HFD-fed rats with or without simvastatin or Neu5Ac (50 and 400 mg/kg/day) were followed up for
12 weeks. Lipid profiles, and markers of inflammation (C-reactive protein, interleukin-6, and tumor necrosis
factor alpha), insulin resistance (serum insulin and adiponectin, oral glucose tolerance test and homeostatic
model of insulin resistance) and oxidative stress (total antioxidant status and thiobarbituric acid reactive
species) in the serum and liver were determined, while mRNA levels of hepatic antioxidant and inflammation
genes were also quantified. Serum levels of alanine transaminase, aspartate transaminase, alkaline phosphatase,
urea, creatinine and uric acid were also assessed.
Results: HFD feeding caused hyperlipidemia and insulin resistance, and worsened liver and kidney functions.
HFD feeding also potentiated inflammation and oxidative stress, partly through modulation of hepatic gene
expression, while Neu5Ac especially at higher doses and simvastatin attenuated HFD-induced changes,
although Neu5Ac showed better outcomes.
Conclusions: Based on the present results, we surmised that Neu5Ac can prevent HFD-induced inflammation and
oxidative stress, and may in fact be useful in the prevention of hyperlipidemia-associated inflammation and oxidative
stress. However, the translational implications of these findings can only be determined after long-term effects are
established. Hence, the use of Neu5Ac on obesity-related diseases requires additional attention.
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Background
Sialic acids (SAs) are small aminosaccharides that
consist of a neuraminic acid backbone with one or
multiple O- or N-linked side chains, the most abun-
dant of which is N-acetylneuraminic acid (Neu5Ac) in
humans. SAs are abundantly present in many human
tissues and fluids [1–3], and a positive association be-
tween elevated SA levels and coronary artery disease
(CAD) has been demonstrated [4–6]. This association
may be mediated through CAD risk factors, including
changes in serum cholesterol concentrations [7, 8].
Higher levels of SA have also been linked with in-
flammation [3] and positively correlated with erythro-
cyte sedimentation rate [9, 10] and the serum
concentration of C-reactive protein [8]. Although total
serum SA is a sensitive marker of acute phase
* Correspondence: mustyimam@gmail.com; myhome.e@gmail.com
1Laboratory of Molecular Biomedicine, Institute of Bioscience, Universiti Putra
Malaysia, 43400 Serdang, Selangor, Malaysia
Full list of author information is available at the end of the article
© 2015 Yida et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Yida et al. Journal of Biomedical Science  (2015) 22:96 
DOI 10.1186/s12929-015-0211-6
reactions, it is non-specific because SA is present in
many acute phase proteins. On the flip side, there are
suggestions that as an acute response marker, SA is
simply useful as a substrate for the resialylation of
vascular endothelium, in an attempt to reverse ath-
erosclerosis [11]. Despite extensive studies on the
implications of endogenous SA levels, not much has
been reported on the effects of dietary supplementa-
tion on health outcomes.
Studies have indicated that dietary supplementation
with N-glycolylneuraminic acid (Neu5Gc) may promote
inflammation, hepatocellular cancer and hemolytic-
uremic syndrome [12, 13], while supplementation with
Neu5Ac has been shown to promote brain development
and improve salivation [14, 15]. Based on the widespread
presence of Neu5Ac in body fluids and the hypothesis
that its elevation as an acute phase marker may be an
attempt to enhance the resialylation of vascular endothe-
lium and reduce inflammation, we decided to evaluate
its effects on inflammation and oxidative stress in rats.
Moreover, there is increasing interest in alternative ther-
apies targeting cardiovascular disease risk factors, in-
cluding inflammation and oxidative stress. The need for
safer and more cost-effective therapies has been the
driving force behind this new trend [16].
Methods
Materials
Standard rat pellet was purchased from Specialty
feeds (Glen Forrest, WA, USA), while cholesterol was
purchased from Amresco (Solon, OH, USA) and cho-
lic acid was purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Palm oil was purchased
from Yee Lee Edible oils Sdn. Bhd. (Perak, Malaysia),
and simvastatin and sialic acid (Neu5Ac) were pur-
chased from Pfizer (New York, NY, USA) and Carbo-
synth Limited (Compton, Berkshire, UK), respectively.
ELISA kits (Insulin, adiponectin, CRP, IL-6 and TNF-
α) were purchased from Elabscience Biotechnology Co.,
Ltd (Wuhan, China) while 1,1,3,3-tetramethoxypropane
(TMP), thiobarbituric acid, potassium persulfate (K2S2O8),
2,2’-azino-bis[3-ethylbenzothiazoline-6-sulphonic acid]
(ABTS) reagent, trolox standard and trichloroacetic acid
were purchased from Sigma Aldrich (St. Loius, MO, USA).
The RNA extraction and GenomeLab™ GeXP Start Kits
were purchased from RBC Bioscience Corp. (Taipei,
Taiwan) and Beckman Coulter Inc. (Miami, FL, USA),
respectively. Lipid profile, uric acid, alkaline phosphat-
ase (ALP), aspartate transaminase (AST), and alanine
transaminase (ALT), urea and creatinine analytical
kits were purchased from Randox Laboratories Ltd
(Crumlin, County Antrim, UK). RCL2 Solution was
purchased from Alphelys (Toulouse, France), while
analytical grade ethanol was purchased from Merck
(Darmstadt, Germany). All other solvents were of analyt-
ical grade and purchased from Merck (Darmstadt,
Germany).
Animal study
Approval for the use of animals for the present study
was given by the Animal Care and Use Committee
(ACUC) of the Faculty of Medicine and Health Sci-
ences, Universiti Putra Malaysia (Serdang, Selangor,
MY), with project approval number: UPM/IACUC/
AUP-R011/2014. Animals were handled as stipulated
by the guidelines for the use of animals set by the
ACUC of the faculty. Ten-week old male Sprague
Dawley rats (n = 30, body weights between 230–
280 g), were housed in individual cages and main-
tained at room temperature (25 ± 2 °C, 12/12 h light/
dark cycle). Rats were acclimatized for 2 weeks with
free access to water and normal pellet, and were then
divided into 5 groups, (6 rats/group) as shown in
Table 1. The normal group received normal rat pellet
throughout the 12 weeks of intervention, while the
rest of the groups received a high fat diet (HFD)
alone, HFD + simvastatin (10 mg/kg/day) [17], HFD +
low dose Neu5Ac/SA (50 mg/kg/day) or HFD + high
dose Neu5Ac/SA (400 mg/kg/day). Food intake was
measured daily while body weights were measured
every week. At the end of the intervention, rats were
sacrificed after an overnight fast, and their blood and
organs were stored for further studies.
Lipid profile, liver enzymes, uric acid, urea and creatinine
Serum lipid profile, liver enzymes (ALP, AST, and ALT),
uric acid, urea and creatinine analyses were performed
using Randox analytical kits according to manufacturer’s
instructions on a Selectra XL instrument (Vita Scientific,
Dieren, The Netherlands).
Oral glucose tolerance test (OGTT), serum insulin and
adiponectin, and homeostatic model of insulin resistance
(HOMA-IR)
OGTT was done after an overnight fast using a gluc-
ometer (Roche Diagnostics, Indianapolis, IN, USA),
while serum insulin and adiponectin levels were mea-
sured using ELISA kits according to the manufacturer’s
instructions. The absorbance for ELISA analysis was
read on a BioTeK Synergy H1 Hybrid Reader (BioTek
Instruments Inc., Winooski, VT, USA) at 450 nm and
the results were analyzed on www.myassays.com using
four parametric test curve (Insulin: R2 = 1; adiponectin:
R2 = 0.99). Furthermore, HOMA-IR was computed from
the fasting plasma glucose and insulin levels using the
formula, HOMA-IR = (fasting glucose level [mg/dL]/
fasting insulin [uU/mL])/2430 [18].
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Serum C-reactive protein (CRP), interleukin 6 (IL-6) and
tumor necrosis factor alpha (TNF-α)
Serum CRP, IL-6 and TNF-α were measured using the re-
spective ELISA kits according to the manufacturers’ in-
structions. Absorbance was read on BioTeK Synergy H1
Hybrid Reader (BioTek Instruments Inc., Winooski, VT,
USA) at 450 nm. Results were computed into fold changes
by dividing the results of the different groups with those
of the normal group.
Serum total antioxidant status
Total antioxidant status was measured using ABTS
radical scavenging activity assay. Briefly, 2.45 mM po-
tassium persulfate (K2S2O8) solution was prepared
using 6.62 mg K2S2O8 dissolved in 10 mL of distilled
water, while 7 mM ABTS solution was prepared by
dissolving 38.4 mg ABTS in 10 mL distilled water.
The two solutions were mixed and incubated for 16 h
in the dark. The mixture was then diluted using dis-
tilled water to obtain a spectrophotometric absorb-
ance of 0.700 ± 0.005 at 735 nm. Furthermore, serum
samples (100 μL) or trolox (100 μL) were mixed with
900 μL of the diluted ABTS solution, and their
absorbance read at 735 nm. The ABTS radical cation
scavenging activity was expressed as the percentage
reduction in absorbance.
Liver Thiobarbituric acid reactive species (TBARS)
Liver tissue TBARS was measured as reported by Chan
et al. [19] with minor modifications. Briefly, liver tissue
(80 mg) was homogenized in 250 μL of 0.25Hcl, 250 μL
of 0.375 % thiobarbituric acid and 250 μL of 15 % tricho-
loroacetic acid, and the mixture was incubated at 100 °C
for 10 min. Subsequently, the mixture was cooled down
and centrifuged at 3,000 rpm for 15 min. Finally, 100 μL
of each sample and standard (TMP) was loaded into a
96-well plate and the absorbance was read at 532 nm
using BioTeK Synergy H1 Hybrid Reader (BioTek
Instruments Inc., Winooski, VT, USA). Results were
expressed as μM MDA/mg tissue.
Gene expression study
Primers were designed on the National Center for Biotech-
nology Information website (http://www.ncbi.nlm.nih.gov/
nucleotide/) using the Rattus norvegicus gene sequences.
All primer sequences were tagged with 18-nucleotide
universal forward and 19-nucleotide universal reverse
sequences, respectively. Primers (Table 2) were supplied by
Table 2 Names, accession numbers and primer sequences used in the study
Name Left sequence Right sequence
nfkb1 AGGTGACACTATAGAATACACTCCATATTTAATGCAGA GTACGACTCACTATAGGGAGAAATCCTCTCTGTTTCG
B2ma AGGTGACACTATAGAATAATGCTTGCAGAGTTAAACA GTACGACTCACTATAGGGATGCATAAAATATTTAAGGTAAGA








aHousekeeping genes. bNormalization gene. Underlined sequences are left and right universal sequences (tags). cinternal control supplied by Beckman Coulter Inc
(Miami, FL, USA) as part of the GeXP kit. RT conditions were: 48 °C for 1 min; 37 °C for 5 min; 42 °C for 60 min; 95 °C for 5 min, then hold at 4 °C. PCR conditions
were initial denaturation at 95 °C for 10 min, followed by two-step cycles of 94 °C for 30 s and 55 °C for 30 s, ending in a single extension cycle of 68 °C for 1 min





Palm oil (%) Starch (%) Others Food intake
g/kg/day Kcal/kg/day
Normal 100 64.34 ± 10.96 215.54 ± 33.5a
Untreated control 65 5 20 10 48 ± 8.36 215.04 ± 37.45a
(HFD)
HFD + SIM 65 5 20 10 Simvastatin (10 mg/kg/day) 48.14 ± 8.17 215.67 ± 36.60a
HFD + SAL 65 5 20 10 50 mg/kg/day sialic acid 48.25 ± 8.32 216.16 ± 37.27a
HFD + SAH 65 5 20 10 400 mg/kg/day sialic acid 48.11 ± 8.12 215.53 ± 36.38a
Data represent mean ± SD (n = 6). Different alphabets in each column indicate significant difference (p < 0.05) using Tukey’s multiple comparison test. HFD: high
fat diet; HFD + SAL: HFD+ 50 mg sialic acid/kg/day; HFD + SAH: HFD + 400 mg sialic acid/kg/day
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Integrated DNA Technologies (Singapore), and stored
at −20 °C prior to using them for the gene expression
study. Hepatic RNA was extracted using the Total
RNA extraction kit (RBC Bioscience Corp., Taipei,
Taiwan) according to the manufacturer’s instructions,
and was used (20 ng/mL) for reverse-transcription
and PCR according to the GenomeLab™ GeXP Start
Kit protocol (Beckman Coulter, USA), as detailed in
Table 2. Then, 1 μL of the PCR products was mixed
with sample loading buffer and DNA size standard-
400 and analyzed on the GeXP genomelab genetic
analysis system (Beckman Coulter, Inc, Miami, FL,
USA). The gene expression results were finally nor-
malized using the Fragment Analysis module of the
GeXP system software and the eXpress Profiler
software.
Data analysis
The data expressed as means ± standard deviation
were analyzed using one-way analysis of variance
(ANOVA) with Tukey Post-hoc comparisons on SPSS
17.0 software (SPSS Inc., Chicago, IL, USA). Here, p
< 0.05 was considered statistically significant.
Results and discussions
Effects of Neu5Ac on food intake and body weights
Food intake remained similar between the groups
throughout the period of intervention (Table 1). And
Table 3 Lipid profile and insulin resistance index
Rat groups Chol. (mmol/L) Trig. (mmol/L) LDL (mmol/L) HDL (mmol/L) Insulin (pg/mL) HOMA-IR Adiponectin (ng/mL)
Normal 1.55 ± 0.43a 0.62 ± 0.15a 0.28 ± 0.11a 1.18 ± 0.35a 495 ± 51.3a 1.91 ± 0.23a 72.9 ± 0.7a
Untreated control 7.47 ± 1.13b 1.21 ± 0.38b 4.98 ± 1.03b 1.05 ± 0.13a 513.3 ± 38.8a 2.46 ± 0.22b 61.8 ± 6.8b
(HFD)
HFD + SIM 4.99 ± 1.11c 0.63 ± 0.18a 3.6 ± 1.1b 1.04 ± 0.17a 602.1 ± 145.7a 2.83 ± 0.79a,b 53.3 ± 0.4c
HFD + SAL 5.68 ± 2.18b,c 0.54 ± 0.07a 4.48 ± 1.81b 1.04 ± 0.28a 521.25 ± 118.65a 2.12 ± 0.56a,b 68.1 ± 1.0b,d
HFD + SAH 5.05 ± 2.07b,c 0.54 ± 0.07a 3.67 ± 1.58b 1.08 ± 0.27a 512.77 ± 90.3a 2.08 ± 0.42a,b 73.9 ± 5.8a,d
Data represent mean ± SD (n = 6). The high fat diet-induced hypercholesterolemia attenuated by sialic acid supplementation, although it was only statistically
different for the triglycerides (p < 0.05). Serum insulin levels were similar among all groups, but the insulin resistance index (HOMA-IR) indicated better insulin
sensitivity in the sialic acid groups in comparison with the untreated control group. High fat diet-induced hypoadiponectinemia was also attenuated by sialic acid
supplementation. For each parameter in a column, different superscript letters indicate statistical difference between any 2 groups (p < 0.05) using Tukey’s multiple
comparison test. Groups are the same as Table 1. HDL: high-density lipoprotein; HFD: high fat diet; HOMA-IR: homeostatic model assessment of insulin resistance;
LDL: low-density lipoprotein; Chol: cholesterol; SAH: high dose sialic acid; SAL: low dose sialic acid; SIM: Simvastatin; Trig: triacylglycerol
Fig. 1 Body weight changes in high fat diet-fed rats over 12 weeks of intervention. Groups are the same as Table 1
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although there were no significant differences ob-
served in the body weights of the different groups
(Fig. 1), the untreated control (HFD) group had the
highest body weight gain in comparison with the
other groups. Moreover, body weight gain is an im-
portant factor in the development of oxidative stress,
which helps to explain the association between oxi-
dative stress and obesity [20]. The high dose SA
(SAH) group showed the lowest weight gain, sug-
gesting that Neu5AC could have some influence on
HFD-induced weight gain. Dietary supplementation
with Neu5AC could have influenced weight through
differential sialylation of glycoprotein structures
across the body [11].
Effects of Neu5Ac on lipid profile, serum insulin and
adiponectin, and insulin resistance index
Dyslipidemia and insulin resistance are associated with
an increased risk of cardiovascular disease, while im-
provements in these factors are reported to prevent car-
diovascular disease [21]. In this study, HFD feeding
worsened lipid profiles (Table 3) and insulin resistance
Fig. 3 Serum alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), urea, creatinine and uric acid in high fat diet-fed rats
after 12 weeks of intervention. Groups are the same as Table 1. * indicates statistically significant difference in comparison with the untreated (high fat
diet) group (p < 0.05) in each panel
Fig. 2 Oral glucose tolerance test in high fat diet-fed rats after 12 weeks
of intervention. Groups are the same as Table 1. * indicates statistically
significant difference (p < 0.05) in comparison with the untreated (high
fat diet) group
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(HOMA-IR [Table 3] and OGTT [Fig. 2]) although
serum insulin levels remained the same for the groups
(Table 3), while supplementation with Neu5Ac attenu-
ated the HFD-induced changes. However, among the
lipid profiles, only triglycerides were significantly lower
in the Neu5Ac groups in comparison with the HFD
group. Worsening of lipid profiles, as seen in the
untreated control group, is linked to cardiometabolic
diseases, while improved levels are important thera-
peutic and preventive measures [21]. Additionally, the
OGTT results for the Neu5Ac-treated groups showed
significantly better insulin sensitivity in comparison with
the normal, simvastatin and HFD groups (Fig. 2). Serum
adiponectin levels were reduced in the untreated control
group (Table 3), in keeping with increased risk of cardio-
metabolic diseases [22]. Although simvastatin improved
lipid profiles, it worsened serum adiponectin levels,
which partly explains the basis for the worsening of
metabolic indices and increased risk of insulin resistance
due to simvastatin [23]. Moreover, adiponectin is an
important regulator of metabolism, and has been shown
to modulate various pathways with resultant improve-
ments in metabolic outcomes, while its reduction has
been linked with worsening cardiometabolic outcomes
[22]. Overall, the improved lipid profiles, serum adipo-
nectin and insulin sensitivity in the Neu5Ac groups is
indicative of the potential of Neu5Ac supplementation
to prevent HFD-induced metabolic perturbations and
cardiovascular diseases. As suggested earlier, these
changes may have been due to differential sialylation of
glycoproteins with consequent implications for different
metabolic pathways [24, 25].
Effects of Neu5Ac on liver enzymes, urea and creatinine
Liver enzymes, kidney function markers (urea ad cre-
atinine) and serum uric acid are shown in Fig. 3. HFD
feeding worsened serum AST, ALT, ALP, urea and uric
acid levels, while creatinine remained the same. The
Fig. 4 Serum markers of inflammation (CRP:C-reactive protein; IL6:interleukin 6; TNF-α:tumor necrosis factor alpha) in high fat diet-fed rats after
12 weeks of intervention. Groups are the same as Table 1. * indicates statistically significant difference in comparison with the untreated (high fat
diet) group (p < 0.05) in each panel
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levels of these markers were significantly improved by
supplementation with Neu5Ac and were comparable to
the normal group. Interestingly, simvastatin improved
lipid profiles but the data showed that it did not improve
liver or kidney functions. The roles of the liver and
kidneys in maintaining homeostasis are well established.
These organs are the targets of cardiometabolic pertur-
bations and their affectation has been shown to further
propagate these diseases [26, 27]. The worsened liver
and kidney functions in the untreated and simvastatin
groups suggested deterioration in their functions, while
the improved markers in the Neu5Ac groups indicated
that its supplementation could protect or assist in the
regeneration of hepatocytes.
Effects of Neu5Ac on serum markers of inflammation and
oxidative stress
Inflammatory markers such as serum CRP, IL-6 and TNF-α
have a significant relationship with cardiovascular disease
[28]. In this study, there were significant increases in serum
CRP, IL-6 and TNF-α in the HFD group compared with
the simvastatin and Neu5Ac groups (Fig. 4). Simvastatin
and Neu5AC showed modest reductions in inflamma-
tory markers, although only simvastatin significantly
reduced CRP, while both interventions (simvastatin
and Neu5AC) reduced IL-6 and TNF-α significantly
to similar degrees. Inflammation is reported to pro-
mote cardiovascular disease, although there have been
suggestions that cardiovascular disease may in fact be
a manifestation of inflammation [28], which can be
induced by the consumption of a high fat diet [29].
Simvastatin has previously been shown to possess
anti-inflammatory effects [30], and the present results
showed that dietary Neu5AC may have similar poten-
tials for the attenuation of inflammation.
Furthermore, markers of oxidative stress were wors-
ened in the HFD group (Fig. 5), as suggested by the in-
creased TBARS and decreased TAS in comparison with
Fig. 5 Oxidative stress markers (serum TAS:total antioxidant status; liver TBARS:thiobarbituric acid reactive species) in high fat diet-fed rats after
12 weeks of intervention. Groups are the same as Table 1. *indicates statistical difference in comparison with the untreated (high fat diet) group
(p < 0.05) in each panel. #indicates statistically significant difference in comparison with the normal group (p < 0.05) in each panel
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the normal group. Simvastatin and Neu5AC, on the
other hand, improved oxidative stress significantly by in-
creasing TAS and reducing TBARS. The results sug-
gested that HFD may promote oxidative stress and
inflammation in addition to weight gain, dyslipidemia
and insulin resistance, while simvastatin and Neu5AC
will prevent such HFD-induced changes. The effects of
simvastatin have been reported previously [30] but this
is the first demonstration of such effects for Neu5AC
supplementation.
Effects of Neu5Ac on mRNA levels of hepatic antioxidant
and inflammation genes
Based on the observations that Neu5AC possessed anti-
oxidative and anti-inflammatory effects, we studied the
potential mechanistic bases for such effects by measuring
Fig. 6 Hepatic mRNA levels of glutathione peroxidase (Gpx), glutathione reductase (Gsr), superoxide dismutase (SOD) 1 and 2 in high fat diet-fed
rats after 12 weeks of intervention. Groups are the same as Table 1. *indicates statistically significant difference in comparison with the untreated
(high fat diet) group (p < 0.05) for each gene. #indicates statistically significant difference in comparison with the normal group (p < 0.05)
for each gene
Fig. 7 Hepatic mRNA levels of C-reactive protein (CRP) and nuclear factor kappa beta (nfkb) in high fat diet-fed rats after 12 weeks of intervention.
Groups are the same as Table 1. *indicates statistically significant difference in comparison with the untreated (high fat diet) group (p < 0.05).
#indicates statistically significant difference in comparison with the normal group (p < 0.05) for each gene
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the mRNA levels of related hepatic genes (Figs. 6 and 7).
The results indicated that HFD feeding decreased mRNA
levels of hepatic antioxidant genes (glutathione peroxidase
[Gpx], and superoxide dismutase [SOD]) (Fig. 6) and in-
creased those of inflammatory genes (CRP and nuclear
factor kappa beta [nfkb]) (Fig. 7). Although simvastatin
and Neu5AC improved mRNA levels of hepatic antioxi-
dant genes, Neu5AC had more profound effects, especially
at higher doses (glutathione reductase [Gsr] and SOD).
Additionally, simvastatin and Neu5AC produced lower
mRNA levels of inflammatory genes, although the CRP
gene expression was not significantly different when com-
pared with the HFD group. However, the mRNA levels of
nfkb1 gene in the simvastatin and Neu5AC groups were
significantly different when compared with the HFD group.
The effects of simvastatin observed in the present
study are in keeping with its reported antioxidant and
anti-inflammatory effects [30]. However, the effects of
simvastatin on liver and kidney functions and insulin
sensitivity indicated that it was not suitable for long-
term use [23]. Neu5AC supplementation, on the other
hand, has not been previously reported to reduce inflam-
mation and oxidative stress induced by HFD feeding.
The present results, therefore, demonstrated for the
first time that Neu5Ac supplementation could prevent
HFD-induced metabolic perturbations, partly through
transcriptional regulation of related hepatic genes.
Disparity between gene expression results and serum
biochemical markers like those of CRP could indicate
that Neu5AC and simvastatin modulate their effects
at transcriptional and non-transcriptional levels, or
that other post-transcriptional modifications are in-
volved in their overall effects.
Conclusions
We demonstrated for the first time that dietary
Neu5Ac supplementation attenuated HFD-induced weight
gain, dyslipidemia, insulin resistance, inflammation and
oxidative stress, partly through the transcriptional regula-
tion of related hepatic genes in rats. In view of the side
effect profile of most pharmaceuticals currently in use, the
present results suggest that Neu5AC supplementation
may be used as a safer alternative for the management of
diseases in which obesity, inflammation and oxidative
stress are central problems, including cardiometabolic dis-
eases. However, further studies are indicated to establish
the long term effects of Neu5Ac supplementation and its
translational implications.
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